Exicure (XCUR)

• Market cap: $17M
• 1 day: -4.98%
• 5 days: -10.4%
• 1 month: -25%
• 3 months: -28.03%
• 6 months: -30.83%
• Year to date: -52.15%
• 1 year: -73.3%
• 5 years: -98.92%
• 10 years: -99.32%
• Sector: Healthcare
• Industry: Biotechnology

About: Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.

Employees: 8